Hervolution pitch at Novo BII demo-day by Peter J. Holst

Hervolution treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where Hervolution is presented by Associate Professor Peter Johannes Holst.

Related news

SIRION Biotech Licenses Adenovirus Technology to Danish Startup, Hervolution for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)